Form 4: Dolby CEO Kevin Yeaman Executes Stock Options and Sells Shares Under 10b5-1 Plan

Dolby Laboratories President and CEO Kevin J. Yeaman reported the exercise of employee stock options and subsequent sale of Class A Common Stock shares on July 15 and 16, 2025, as part of a pre-arranged trading plan.

Summary

• Kevin J. Yeaman, President and CEO and Director of Dolby Laboratories, Inc. (DLB), reported multiple stock transactions on July 15 and 16, 2025, executed under a Rule 10b5-1(c) contract.
• On July 15, 2025, Mr. Yeaman exercised options to acquire 25,000 Class A Common Stock shares at an exercise price of $45.50 and 14,875 shares at an exercise price of $64.60.
• On July 15, 2025, Mr. Yeaman sold 39,595 Class A Common Stock shares at a weighted average price of $74.8126 and 280 shares at a weighted average price of $75.3032.
• On July 16, 2025, Mr. Yeaman exercised options to acquire 2,491 Class A Common Stock shares at an exercise price of $64.60.
• On July 16, 2025, Mr. Yeaman sold 2,491 Class A Common Stock shares at a price of $75.00.
• The total number of shares acquired through option exercises was 42,366, and the total number of shares sold was 42,366.
• Following these transactions, Mr. Yeaman's indirect beneficial ownership through the Kevin and Rachel Yeaman Family Trust remained at 114,725 Class A Common Stock shares.
• Additionally, Mr. Yeaman directly holds 127,735 Class A Common Stock shares underlying restricted stock units, which are subject to forfeiture until they vest.
• An additional 2.5592 Class A Common Stock shares are indirectly beneficially owned by a son.

Sentiment

Score: 5

Explanation: The document reports routine insider stock transactions, including option exercises and sales, which do not inherently indicate positive or negative sentiment about the company's future performance. The transactions appear to be for liquidity or diversification purposes, consistent with a pre-arranged trading plan.

Positives

• The exercise of employee stock options indicates that the options were significantly in-the-money, allowing the executive to realize value from previously granted equity awards.
• Shares acquired through option exercises were sold at prices substantially higher than their exercise prices, generating a significant profit for the reporting person. For example, shares acquired at $45.50 were sold as part of a larger block at an average of $74.8126, and shares acquired at $64.60 were sold at an average of $74.8126 or $75.00.
• The transactions were made pursuant to a Rule 10b5-1(c) plan, which suggests a pre-arranged and systematic approach to managing equity compensation rather than a reaction to immediate market conditions.

Negatives

• The transactions represent a 'sell-to-cover' or liquidity event where shares acquired from option exercises were immediately sold, resulting in no net increase in the executive's overall equity stake in the company through these specific transactions.

Future Outlook

This Form 4 filing reports past insider transactions and does not contain forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This filing is a routine insider transaction report and does not provide specific insights into broader industry trends or competitive dynamics. It reflects an executive's personal equity management.

Related Party Transactions

• Transactions were conducted by Kevin J. Yeaman, President and CEO and Director, and involved shares held indirectly by the Kevin and Rachel Yeaman Family Trust dated May 14, 2009, which is considered a related party.

Stakeholder Impact

• Shareholders may observe that the CEO is realizing value from his equity compensation, which is a common practice. The transactions, being a 'sell-to-cover' type, did not result in a net increase or decrease in the trust's overall beneficial ownership, suggesting a planned liquidity event rather than a change in investment conviction.

Key Dates

Keywords

Dolby Laboratories, DLB, Kevin Yeaman, Form 4, Insider Trading, Stock Options, Stock Sales, Beneficial Ownership, CEO, Director, 10b5-1 Plan